La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 0.00% and -1.04%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) Reports Q2 Loss, Lags Revenue Estimates

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

La Jolla Pharmaceutical announced positive results from its phase 2 study using LJPC-401 to treat patients with hereditary hemochromatosis.

Despite Reporting Data For A Mid-Stage Study, La Jolla Has Several Other Irons In The Fire For 2019

Successful turnaround stories are like Cinderella bioscience stocks. They do not come around often but the profits from a successful turnaround are phenomenal.

La Jolla: A Cinderella Bioscience Innovator

La Jolla Pharmaceutical (LJPC) needs investors to pay close attention to the stock based on moves in the options market lately.

Implied Volatility Surging for La Jolla Pharmaceutical (LJPC) Stock Options

A mid-stage clinical trial has investors excited about the biotech's future.

Here's Why La Jolla Pharmaceutical Has More Than Doubled Over the Last 2 Days

La Jolla Pharmaceutical (LJPC) delivered earnings and revenue surprises of 10.69% and -11.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

La Jolla Pharmaceutical (LJPC) Reports Q1 Loss, Misses Revenue Estimates

La Jolla Pharmaceutical (LJPC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

La Jolla Pharmaceutical (LJPC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Galmed Pharmaceuticals

Inovio Pharmaceuticals

MannKind

Viking Therapeutics

This off-the radar pick could be poised to be a huge winner. Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company.

5 Sizzling Biotech Stocks Under $10 With Gigantic Upside Potential

News for La Jolla Pharmaceutical Stock (LJPC)